{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T09:10:27Z","timestamp":1792228227002,"version":"4.4.0"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T00:00:00Z","timestamp":1741737600000},"content-version":"vor","delay-in-days":11,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","msard-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.msard.2025.106310","type":"journal-article","created":{"date-parts":[[2025,2,2]],"date-time":"2025-02-02T15:09:42Z","timestamp":1738508982000},"page":"106310","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Cognitive effects of ocrelizumab vs interferon \u03b2-1a in relapsing multiple sclerosis: A post hoc analysis of the OPERA I\/II trials"],"prefix":"10.1016","volume":"95","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2080-3631","authenticated-orcid":false,"given":"Ralph HB","family":"Benedict","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludwig","family":"Kappos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Peter","family":"Hartung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Overell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinglan","family":"Pei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Dahlke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corrado","family":"Bernasconi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harold","family":"Koendgen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"Bonati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanley","family":"Cohan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.msard.2025.106310_bib0020","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1177\/1352458511435717","article-title":"Reliability and equivalence of alternate forms for the Symbol Digit Modalities Test: implications for multiple sclerosis clinical trials","volume":"18","author":"Benedict","year":"2012","journal-title":"Mult. Scler."},{"issue":"5","key":"10.1016\/j.msard.2025.106310_bib0012","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1177\/1352458517690821","article-title":"Validity of the symbol digit Modalities Test as a cognition performance outcome measure for multiple sclerosis","volume":"23","author":"Benedict","year":"2017","journal-title":"Mult. Scler."},{"issue":"6","key":"10.1016\/j.msard.2025.106310_bib0019","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1177\/1352458517707345","article-title":"Improved cognitive outcomes in patients with relapsing-remitting multiple sclerosis treated with daclizumab beta: results from the DECIDE study","volume":"24","author":"Benedict","year":"2018","journal-title":"Mult. Scler."},{"issue":"10","key":"10.1016\/j.msard.2025.106310_bib0005","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/S1474-4422(20)30306-9","article-title":"Cognition in multiple sclerosis: Charcot was right","volume":"19","author":"Benedict","year":"2020","journal-title":"Lancet Neurol."},{"issue":"3","key":"10.1016\/j.msard.2025.106310_bib0006","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1212\/CPJ.0000000000000449","article-title":"Identifying priority outcomes that influence selection of disease-modifying therapies in MS","volume":"8","author":"Day","year":"2018","journal-title":"Neurol. Clin. Pract."},{"key":"10.1016\/j.msard.2025.106310_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.104375","article-title":"Repeated forms, testing intervals, and SDMT performance in a large multiple sclerosis dataset","volume":"68","author":"Fuchs","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"3","key":"10.1016\/j.msard.2025.106310_bib0015","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa1601277","article-title":"Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis","volume":"376","author":"Hauser","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"13","key":"10.1016\/j.msard.2025.106310_bib0001","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1177\/1352458518803785","article-title":"Recommendations for cognitive screening and management in multiple sclerosis care","volume":"24","author":"Kalb","year":"2018","journal-title":"Mult. Scler."},{"issue":"22","key":"10.1016\/j.msard.2025.106310_bib0008","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000009522","article-title":"Disease-modifying treatments and cognition in relapsing-remitting multiple sclerosis: a meta-analysis","volume":"94","author":"Landmeyer","year":"2020","journal-title":"Neurology."},{"issue":"11","key":"10.1016\/j.msard.2025.106310_bib0013","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1177\/1352458517723718","article-title":"The MSOAC approach to developing performance outcomes to measure and monitor multiple sclerosis disability","volume":"24","author":"LaRocca","year":"2018","journal-title":"Mult. Scler."},{"issue":"2","key":"10.1016\/j.msard.2025.106310_bib0007","doi-asserted-by":"crossref","first-page":"61","DOI":"10.3390\/pharmacy8020061","article-title":"Assessing pharmacists' preferences towards efficacy attributes of disease-modifying therapies in relapsing-remitting multiple sclerosis","volume":"8","author":"Mart\u00ednez-L\u00f3pez","year":"2020","journal-title":"Pharmacy. (Basel)"},{"key":"10.1016\/j.msard.2025.106310_bib0014","series-title":"Prescribing information","year":"2017"},{"issue":"2","key":"10.1016\/j.msard.2025.106310_bib0016","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/ana.22366","article-title":"Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria","volume":"69","author":"Polman","year":"2011","journal-title":"Ann. Neurol."},{"issue":"1\u20132","key":"10.1016\/j.msard.2025.106310_bib0002","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.jns.2007.10.002","article-title":"Cognitive impairment in different MS subtypes and clinically isolated syndromes","volume":"267","author":"Potagas","year":"2008","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.msard.2025.106310_bib0022","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.msard.2016.09.009","article-title":"Practice effect in symbol digit modalities test in multiple sclerosis patients treated with natalizumab","volume":"10","author":"Roar","year":"2016","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"9","key":"10.1016\/j.msard.2025.106310_bib0003","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1177\/1352458516674367","article-title":"Age and disability drive cognitive impairment in multiple sclerosis across disease subtypes","volume":"23","author":"Ruano","year":"2017","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2025.106310_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.102950","article-title":"The symbol digit modalities test (SDMT) is sensitive but non-specific in MS: lexical access speed, memory, and information processing speed independently contribute to SDMT performance","volume":"51","author":"Sandry","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106310_bib0009","unstructured":"Smith A.; Western Psychological Services. (SMDT) Symbol Digit Modalities Test. Accessed July 16, 2024. https:\/\/www.wpspublish.com\/sdmt-symbol-digit-modalities-test."},{"issue":"13","key":"10.1016\/j.msard.2025.106310_bib0011","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1177\/1352458518808204","article-title":"Symbol Digit Modalities Test: a valid clinical trial endpoint for measuring cognition in multiple sclerosis","volume":"25","author":"Strober","year":"2019","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2025.106310_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103405","article-title":"A much needed metric: defining reliable and statistically meaningful change of the oral version Symbol digit modalities test (SDMT)","volume":"57","author":"Strober","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"6","key":"10.1016\/j.msard.2025.106310_bib0004","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1212\/WNL.0000000000004977","article-title":"Cognition in multiple sclerosis: state of the field and priorities for the future","volume":"90","author":"Sumowski","year":"2018","journal-title":"Neurology."},{"issue":"7","key":"10.1016\/j.msard.2025.106310_bib0017","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1177\/13524585211049397","article-title":"Interpreting change on the symbol digit modalities test in people with relapsing multiple sclerosis using the reliable change methodology","volume":"28","author":"Weinstock","year":"2022","journal-title":"Mult. Scler."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825000549?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825000549?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T04:48:41Z","timestamp":1741841321000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034825000549"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":22,"alternative-id":["S2211034825000549"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2025.106310","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cognitive effects of ocrelizumab vs interferon \u03b2-1a in relapsing multiple sclerosis: A post hoc analysis of the OPERA I\/II trials","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2025.106310","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106310"}}